Izushi and colleagues reported that the release of sRAGE has the potential to attenuate the excessive inflammatory response in acute respiratory distress syndrome (ARDS), and supports the notion that RAGE may be a promising candidate as a molecular target for the treatment of ARDS41. Here, AGER is linked to acute respiratory distress syndrome.